Abstract 553P
Background
Next generation sequencing (NGS) has revolutionised the diagnosis of non-small cell lung cancer (NSCLC) yet it is resource-intensive. Exclusionary testing followed by NGS has been advocated as a cost-effective approach in Asians where EGFR mutations are prevalent. Herein we investigated the approach of plasma EGFR (pEGFR) followed by tissue NGS and compared it to upfront tissue NGS in terms of mutation detection and clinical outcome in a real world setting in Hong Kong.
Methods
We retrospectively reviewed 222 patients diagnosed with advanced NSCLC from October 2021 to April 2023, including 145 cases that performed upfront tissue NGS without prior pEGFR (group 1) and 77 cases that underwent pEGFR (Cobas v2) first. Among the latter group, 48 with positive pEGFR (group 2a) started target therapy while 29 with negative pEGFR (group 2b) proceeded further tissue NGS (Oncomine precision assay). Genomic alterations and clinical data were compared among these approaches.
Results
The median age was 70, 72 and 76 years old for group 1, 2a and 2b respectively. Extrathoracic disease was found in 54%, 90% and 41% of patients in each group. Regarding genomic alterations detected by tissue NGS, sensitising EGFR mutations were found in 39% of cases in group 1, compared to only 7% in group 2b (OR 0.11, p=0.001). Additional driver mutations (EGFR exon 20 insertion, T790M, ALK, BRAF, MET exon 14 skipping, ERBB2 exon 20 insertion and KRAS) were found in 27% of group 1 cases, but up to 52% in group 2b (OR 2.92, p=0.008). For patients with EGFR mutations detected by tissue NGS, 41% had concurrent TP53 or PIK3CA mutation, which are predictive markers. The median time from radiological diagnosis to treatment initiation was 18 days for patients with positive pEGFR compared with 41 days for the counterparts underwent tissue NGS.
Conclusions
The pathway of pEGFR preceding tissue NGS allows early detection of druggable EGFR mutations and initiation of target therapy for patients with extrathoracic NSCLC but lacks simultaneous detection of predictive markers. The liquid-first approach enhances the yield of rare mutations by tissue NGS which is resource-dependent. It benefits regions where tissue biopsy is a rate limiting factor and EGFR mutations are prevalent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract